BPC-157 + TB-500 Information & Coordination for Licensed U.S. Clinics
BPC-157 and TB-500 are peptides that have been discussed in research and compounding contexts. FDA has not approved the BPC-157 or TB-500 bulk drug substances it evaluated as components of approved drug products.
Phoenix Meds Inc. supports licensed healthcare organizations with credential review, documentation, regulatory information, and administrative coordination.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About BPC-157 + TB-500
BPC-157 and TB-500 should not be presented as FDA-approved treatments, either individually or as a combined preparation.
FDA’s 2026 review found insufficient evidence to support BPC-157 for the use it evaluated. For TB-500, FDA reported that it did not identify clinical studies or human exposure data and found insufficient evidence to evaluate effectiveness for the proposed use of wound healing.
For that reason, Phoenix Meds Inc. does not promote BPC-157 + TB-500 for tissue repair, injury recovery, inflammation, wound healing, sports recovery, or other treatment outcomes.
Licensed healthcare professionals should rely on current regulatory information and their own clinical, legal, and professional review when considering investigational substances.
Current FDA and Compounding Status
FDA evaluated BPC-157 free base, BPC-157 acetate, TB-500 free base, and TB-500 acetate in 2026 as part of the section 503A Bulks List process.
For BPC-157, FDA stated that neither the free base nor acetate form has an applicable USP or National Formulary drug-substance monograph and neither is a component of an FDA-approved drug. FDA’s evaluation concluded that the available criteria weighed against placing those substances on the 503A Bulks List.
FDA reached a similar conclusion for TB-500 free base and TB-500 acetate. The agency found no applicable USP/NF drug-substance monograph, no FDA-approved drug containing either substance, and concluded that the available criteria weighed against placement on the 503A Bulks List.
Advisory-committee consideration is not itself the same as a final agency rule, so clinics should check FDA’s current status before relying on a particular compounding pathway.
Why the Specific Substance Matters
Names such as “BPC-157” and “TB-500” can make a product sound more standardized than the regulatory record supports.
FDA noted problems with substance identification and characterization in its evaluations. For TB-500, FDA also explains that different forms can have different physical, chemical, and pharmacological characteristics.
That makes the documentation behind an inquiry important. A clinic needs to know what substance is being discussed, what records support its identity, and what regulatory framework would apply.
Phoenix helps organize that administrative information. We do not make the clinical or legal determination for the clinic.
How Phoenix Meds Supports Licensed Clinics
Our role is on the administrative side.
A licensed healthcare organization may need help reviewing credentials, organizing documentation, checking publicly available regulatory records, or identifying questions that need further review.
Our work may include clinic and provider credential review, organization of supporting records, review of publicly available licensing and regulatory information, administrative communication between professional entities, and identification of matters that should be addressed by the appropriate clinical, regulatory, or legal professionals.
The purpose is to make the review process easier to follow without blurring the responsibilities of the parties involved.
An administrative review is not a certification, treatment recommendation, legal opinion, or representation that a particular product or transaction is permitted.
Documentation and Due Diligence
FDA continues to identify safety concerns involving both substances.
For BPC-157, FDA has cited limited safety information as well as concerns involving immunogenicity, peptide-related impurities, and active pharmaceutical ingredient characterization. For TB-500, FDA reports that human safety data are lacking and identifies potential immunogenicity concerns associated with aggregation and peptide-related impurities.
Phoenix Meds Inc. does not manufacture, test, compound, dispense, ship, or take custody of BPC-157 or TB-500. We also do not certify purity, potency, sterility, authenticity, safety, or clinical suitability.
BPC-157 + TB-500 Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations may contact Phoenix Meds Inc. regarding credential review, documentation, and regulatory information relevant to a professional inquiry. An administrative inquiry is not a medication order and does not establish product availability, compounding eligibility, clinical appropriateness, or approval of a proposed transaction.
Clinic Verification
Licensed healthcare organizations may submit relevant professional and facility credentials for administrative verification.
Documentation Review
Verified clinics may request an administrative review of relevant documentation and publicly available regulatory information.
Licensed Parties
Any prescribing, compounding, dispensing, distribution, shipping, storage, or other regulated medication activity remains the responsibility of the party legally authorized to perform it.
Frequently Asked Questions
Are BPC-157 and TB-500 FDA approved?
FDA’s 2026 materials state that the BPC-157 free base and acetate forms and the TB-500 free base and acetate forms it evaluated are not components of FDA-approved drug products.
Is BPC-157 + TB-500 an FDA-approved combination product?
No FDA-approved BPC-157 + TB-500 combination product is identified in FDA’s current materials.
Are BPC-157 and TB-500 on the 503A Bulks List?
FDA evaluated both sets of substances in 2026, and its evaluations weighed against their inclusion on the 503A Bulks List. Because the regulatory process can change, clinics should verify the current FDA status before relying on a compounding pathway
Does Phoenix Meds Inc. compound or dispense BPC-157 + TB-500?
No. We do not compound, manufacture, dispense, test, ship, or take custody of these substances.
What can Phoenix help with?
We provide administrative support around credentials, documentation, publicly available regulatory information, and professional communication.
Does Phoenix provide dosing or treatment protocols?
No. Phoenix Meds Inc. does not provide patient-specific dosing, treatment protocols, or clinical recommendations.
Does Phoenix Meds guarantee product quality or safety?
No. We do not test or certify BPC-157, TB-500, or preparations containing them.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare entities.
We are not a pharmacy, medical practice, manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It is not medical or legal advice, does not represent BPC-157 or TB-500 as FDA-approved treatments, and does not establish that a particular compounding or distribution pathway is legally available.
U.S. FDA Regulatory References
- July 23–24, 2026 Pharmacy Compounding Advisory Committee
- BPC-157-Related Bulk Drug Substances — FDA Briefing Document
- TB-500-Related Bulk Drug Substances — FDA Briefing Document
- Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act